Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques

Vaccine

Volumn 28, Issue 39, 2010, Pages 6483-6490

  Traina Dorge, V ^a   Pahar, B ^b   Marx, P ^a,b   Kissinger, P ^b   Montefiori, D ^c   Ou, Y ^d   Gray, W L ^d  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b TULANE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Simian immunodeficiency virus; Simian varicella virus; Varicella zoster virus

Indexed keywords

CHICKENPOX VACCINE; ENVELOPE PROTEIN; GAG PROTEIN; LIVE VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT SIMIAN VARICELLA VIRUS VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CHICKENPOX; CONTROLLED STUDY; HUMORAL IMMUNITY; MACACA; MALE; NONHUMAN; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN VARICELLA VIRUS; SIMIAN VIRUS; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS LOAD; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CHICKENPOX VACCINE; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; IMMUNITY, CELLULAR; INTERFERON-GAMMA; MACACA MULATTA; MALE; NEUTRALIZATION TESTS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VERO CELLS; VIRAL LOAD;

EID: 77956397418     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.018     Document Type: Article

References (44)

1. United Nations AIDS (UNAIDS). AIDS epidemic update, December 2009. 2009.
2. Kresge K.J. A STEP back?. IAVI Rep 2007, 11(5):1-5.
3. Grose C. Varicella vaccination of children in the United States: an assessment after the first decade 1995-2005. J Clin Virol 2005, 33:89-98.
4. Levin M.J., Gershon A.A., Weinberg A., Song L.Y., Fentin T., Nowak B., et al. Administration of live varicella vaccine to HIV infected children with current or past significant depression of CD4+ T-cells. J Infect Dis 2006, 194:247-255.
5. Bekker V., Westerlaken G.H., Scherpbier H., Alders S., Zaaijer H., van Baarle D., et al. Varicella vaccination in HIV-1 infected children after immune reconstitution. AIDS 2006, 20:2321-2329.
6. Son M., Shapiro E.D., LaRussa P., Neu N., Michalik D.E., Meglin M., et al. Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis 2010, 201:1806-1810.
7. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284.
8. Arvin A.M., Mallory S., Moffat J.F. Development of recombinant varicella-zoster virus vaccines. Contrib Microbiol 1999, 3:193-200.
9. Gray W.L. Simian varicella: a model for human Varicella-zoster virus infections. Rev Med Virol 2004, 14:363-381.
10. Gray W.L. Simian varicella in old world monkeys. Comp Med 2008, 58:22-30.
11. Fletcher T.M., Gray W.L. Simian varicella virus: characterization of virion and infected cell polypeptides and the antigenic cross-reactivity with Varicella-zoster virus. J Gen Virol 1992, 73:1209-1215.
12. Gray W.L., Pumphrey C.Y., Ruyechan W.T., Fletcher T.M. The simian varicella virus and varicella-zoster virus genomes are similar in size and structure. Virology 1992, 186:562-572.
13. Ou Y., Traina-Dorge V., Davis K.A., Gray W.L. Recombinant simian varicella vaccines induce immune responses to simian immunodeficiency virus (SIV) antigens in imunized vervet monkeys. Virology 2007, 364(2):291-300.
14. Allen W.P., Felsenfeld A.D., Wolf R.H., Smetana H.F. Recent studies on the isolation and characterization of delta herpesvirus. Lab Anim Sci 1974, 24:222-228.
15. Smith S.M., Mefford M., Sodora D., Klase Z., Singh M., Alexander N., et al. Topical estrogen protects against SIV vaginal transmission without evidence of systemic effect. AIDS 2004, 18:1637-1643.
16. Ward T.M., Traina-Dorge V., Davis K.A., Gray W.L. Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenic. J Gen Virol 2008, 89:741-750.
17. Knapp L.A., Lehmann E., Piekarczyk M.S., Urvater J.A., Watkins D.I. A high frequency of Mamu-Az.ast;01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 1997, 50:657-661.
18. Gray W.L., Williams R.J., Chang R., Soike K.F. Experimental Simian varicella virus infection of St Kitts vervet monkeys. J Med Primatol 1998, 27:177-183.
19. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and HIV in luciferase reporter assays. Current protocols in immunology 2004, 12.11.1-12.11.15. John Wiley & Sons. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, R. Coico (Eds.).
20. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79:10108-10125.
21. Brandt S.M., Marian R., Holland A.U., Hope T.J., Landau N.R. Association of chemokine-mediated block to HIV entry with co-receptor internalization. J Biol Chem 2002, 277:17291-17299.
22. Pahar B., Lackner A.A., Piatak M., Lifson J.D., Wang X., Das A., et al. Control of viremia and maintenance of intestinal CD4 (+) memory T-cells in SHIV (162P3) infected macaques after pathogenic SIV (mac251) challenge. Virology 2009, 387(2):273-284.
23. Pahar B., Lackner A.A., Veazey R.S. Intestinal double-positive CD4+CD8+ T-cells are highly activated memory cells with an increased capacity to produce cytokines. Eur J Immunol 2006, 36:583-592.
24. Kinchington P.R., Ling P., Pensiero M., Gershon A., Hay J., Ruyechan W.T. A possible role for glycoprotein gpV in the pathogenesis of Varicella-Zoster Virus. Immunobiology and prophylaxis of human herpesvirus infections 1990, 83-91. Plenum Press, New York. C. Lopez (Ed.).
25. Moffat J.F., Zerboni L., Kinchington P., Grose C., Kaneshima H., Arvin A.M. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol 1998, 72:965-974.
26. Grinfeld E., Ross A., Forster T., Ghazal P., Kennedy P.G.E. Genome-wide reduction in transcriptomal profiles of varicella-zoster virus vaccine strains compared with parental Oka strain using long oligonucleotide microarrays. Virus Genes 2009, 38:19-38.
27. Kinchington P.R., Ling P., Pensiero M., Moss B., Ruyechan W.T., Hay J. The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka). J Virol 1990, 64:4540-4548.
28. Egan M.A., Chong S.Y., Rose N.F., Megati S., Lopez K.G., Schadeck E.B., et al. Immunogenicity of attenuated vesicular stomatits virus vectors expressing HIV type 1 env and SIV gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 2004, 20:989-1004.
29. Johnston R.E., Johnson P.R., Connell M.J., Montefiori D.C., West A., Collier M., et al. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine 2005, 23:4969-4979.
30. Carnero E., Li W., Borderia A.V., Moltedo B., Moran T., Garcia-Sastre A. Optimization of human immunodeficiency virus gag expression by Newcastle disease virus vectors for the induction of potent immune responses. J Virol 2009, 83:584-597.
31. Ourmanov I., Kuwata T., Goeken R., Goldstein S., Iyengar R., Buckler-White A., et al. Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiecy virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody. J Virol 2009, 83:5388-5400.
32. Pal R., Venzon D., Letvin N., Santra S., Montefiori D.C., Miller N.R., et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatability complex class I (Az.ast;01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 2002, 76:292-302.
33. Hel Z.K., Nacsa J., Tryniszewska E., Tsai W.-P., Washington-Parks R., Montefiori D.C., et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T-cell responses. J Immunol 2002, 169:4778-4787.
34. Johnson P.R., Schnepp B.C., Connell M.J., Rohne D., Robinson S., Krivulka G.R., et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 2005, 79:955-965.
35. Connor R.I., Montefiori D.C., Binley J.M., Moore J.P., Bonhoeffer S., Gettie A., et al. Temporal analysis of viral replication, immune responses and efficacy in rhesus monkeys immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 1998, 72:7501-7509.
36. Wyand M.S., Manson K., Montefiori D.C., Lifson J.D., Johnson R.P., Desrosiers R.C. Protection by live attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999, 73:8356-8363.
37. Shacklett B.L., Shaw K.E.S., Adams L.A., Wilkens D.T., Cox C.A., Montefiori D.C., et al. Live, attenuated simian immunodefieciency virus SIVmac-M4, with point mutations in the env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenges with pathgenic SIVmac251. J Virol 2002, 76:11365-11378.
38. Messaoudi I., Barron A., Wellish M., Engelmann F., Legasse A., Planer S., et al. Simian varicella virus infection of rhesus macaques recapitulates essential features of varicella-zoster virus infection in humans. PLOS Pathogens 2009, 5.:e1000657. 10.1371/journal. ppat.1000657.
39. Smith S.M., Holland B., Russo C., Dailey P.J., Marx P.A., Connor R.I. Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression. AIDS Res Hum Retrov 1999, 15:1691-1701.
40. Chakraborty R., Morel A.S., Sutton J.K., Appay V., Ripley R.M., Dong T., et al. Correlates of delayed disease progression in HIV-1 infected Kenyan children. J Immunol 2005, 174:8191-8199.
41. Mannioui A., Bourry O., Sellier P., Delache B., Brochard P., Andrieu T., et al. Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques. Retrovirol 2009, 6:106.
42. Staprans S.I., Barry A.P., Silvestri G., Safrit J.T., Kozyr N., Sumpter B., et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T-cell response to the SIV envelope protein. Proc Natl Acad Sci USA 2004, 101:13026-13031.
43. Murphy C.G., Lucas W.T., Means R.E., Czajak S., Hale C.L., Lifson J.D., et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 2000, 74:7745-7754.
44. Shiraki K., Sato H., Yoshida Y., Yamamura J., Tsurita M., Kurokawa M., et al. Construction of Oka varicella vaccine expressing human imunodeficiency virus env antigen. J Med Virol 2001, 64:89-95.